New Therapeutic Options Enhance Breast Cancer Treatment: ASCO Reports
Three Cancer Centers Test Targeted Therapy For Resistant Acute Myelogenous Leukemia
Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer
Study Finds No Link Between Pill And Breast Cancer Risk
Vasectomy Doesn’t Increase Prostate Cancer Risk
Drug Slows Tumor Growth In Metastatic Kidney Cancer
STI-571 Effects Are Lasting Against GI Stromal Tumors
Monoclonal Antibody Improves AML Response To Therapy
Protocols Approved During the Month of June 2002
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
